Healthcare

Revenue from ordinary activities increased 68% to AUD 8.004 million for the year ended 30 June 2026. At the same time, the annual loss attributable to shareholders reached AUD 107.242 million, compared with approximately AUD 64.3 million in FY25. Revenue growth therefore did not …

Nurix Therapeutics (NASDAQ:NRIX) traded at USD 18.55 in pre-market trading on November 4, 2026, down 28.16% or USD 7.27 from the Tuesday, November 3, 2026 close. That points to a prior close of about USD 25.82 (calculated). The likely trigger is a company release …

No company announcement dated November 3 or November 4, 2026 was located in the research, so the decline is not linked to a confirmed catalyst. A plausible backdrop is profit-taking after a sharp run that followed the reverse stock split.

The move appears to be tied to a company press release issued at 4:01 p.m. ET on November 3, 2026, after the regular session ended. In it, the company said Sanofi (NASDAQ:SNY) had notified it that the Phase 1 first-in-human trial of SAR448272, an …

The company released its third quarter 2026 results and corporate update on November 3, 2026, and the selloff appears to reflect a much wider quarterly loss, though no single cause has been confirmed.

No press release or regulatory filing dated November 2 to November 4, 2026 was identified as a catalyst, and the company has not confirmed a date for its third quarter report. With no company news in view, the move looks like sentiment or sector …

The study involved 20 patients, with clinical success of 100% (20 of 20) and technical success of 95%. No major adverse events were reported through 30 days. The company has not linked the share move to the release, so that timing link is an …